ArticleFrontiers in microbiology2025
SXP01: a novel bacteriophage for combating
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The emergence of multi-drug resistant Methods: A novel bacteriophage, SXP01, was isolated using S. xiamenensis A001 as a host. Its kinetic parameters (MOI, latent period) and stability across temperature (4-60°C), pH (6-11), and chloroform were characterized. The lysis cassette was identified genomically, and a recombinant endolysin (LysSXP-1) was expressed to test lytic activity. In vivo efficacy was evaluated in a crucian carp infection model. Results: SXP01, a Myoviridae member, showed an optimal MOI of 0.1, a 20-minute latent period, and high environmental stability. Its lysis cassette encodes two endolysins, with LysSXP-1 demonstrating direct lytic activity. In the fish model, SXP01 treatment significantly increased survival rates from 13.3% to 56.7%. Discussion: The study identifies SXP01 as a highly stable and effective bacteriophage. The synergistic action of its endolysins and its demonstrated in vivo efficacy highlight its strong potential as a targeted biocontrol agent to manage
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.